|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?显示文摘Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC. | Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini | 2018 | World Journal of Gastroenterology2018，24，36： | 14 |
| 2 | Staging systems of hepatocellular carcinoma:A review of literature显示文摘Hepatocellular carcinoma(HCC)is a major health problem with a high incidence and mortality all over the world.Natural history of HCC is severe and extremely variable,and prognostic factors influencing outcomes are incompletely defined.Over time,many staging and scoring systems have been proposed for the classification and prognosis of patients with HCC.Currently,the non-ideal predictive performance of existing prognostic systems is secondary to their inherent limitations,as well as to a non-universal reproducibility and transportability of the results in different populations.New serological and histological markers are still under evaluation with promising results,but they require further evaluation and external validation.The aim of this review is to highlight the main tools for assessing the prognosis of HCC and the main concerns,pitfalls and warnings regarding its staging systems currently in use. | Marcello Maida Emanuele Orlando Calogero Cammà Giuseppe Cabibbo | 2014 | World Journal of Gastroenterology2014，20，15： | 11 |
| 3 | untreatable hepatocellular 癌的自然历史: 回顾的队研究显示文摘 AIM:To investigate the clinical course of untreatable hepatocellular carcinoma(HCC) identified at any stage and to identify factors associated with mortality.METHODS:From January 1999 to December 2010,320 out of 825 consecutive patients with a diagnosis of HCC and not appropriate for curative or palliative treatments were followed and managed with supportive therapy.Cirrhosis was diagnosed by histological or clinical features and liver function was evaluated according to Child-Pugh score.The diagnosis of HCC was performed by Ultra-Sound guided biopsy or by multiphasic contrast-enhanced computed tomography or gadolinium-enhanced magnetic resonance imaging.Data were collected for each patient including all clinical,laboratory and imaging variables necessary for the outcome prediction staging systems considered.HCC staging was performed according Barcelona Clinic Liver Cancer(BCLC) and Cancer of the Liver Italian Program scores.Follow-up time was defined as the number of months from the diagnosis of HCC to death.Prognostic baseline variables were analyzed by multivariate Cox analysis to identify the independent predictors of survival.RESULTS:Seventy-five per cent of patients had hepatitis C.Ascites was present in 169 patients(53%),while hepatic encephalopathy was present in 49 patients(15%).The Child-Pugh score was class A in 105 patients(33%),class B in 142 patients(44%),and class C in 73 patients(23%).One hundred patients(31%) had macroscopic vascular invasion and/or extrahepatic spread of the tumor.A single lesion > 10 cm was observed in 34 patients(11%),while multinodular HCC was present in 189 patients(59%).Thirty nine patients(12%) were BCLC early(A) stage,55(17%) were BCLC intermediate(B) stage,124(39%) were BCLC advanced(C) stage,and 102(32%) were endstage BCLC(D).At the time of this analysis(July 2011),28(9%) patients were still alive.Six(2%) patients who were lost during follow-up were censored at the last visit.The overall median survival was 6.8 mo,and the 1-year survival was 32%.The 1-year survival according to BCLC classes was 100%,79%,12% and 0%,for BCLC A,B,C and D,respectively.There was a significant difference in survival between each BCLC class.The median survival of patients of BCLC stages A,B,C and D was 33,17.4,6.9,and 1.8 mo,respectively(P < 0.05 for comparison between stages).The median survival of Child-Pugh A,B and C classes were 9.8 mo(range 6.4-13),6.1(range 4.9-7.3),and 3.7(range 1.5-6),respectively(P < 0.05 for comparison between stages).By univariate analysis,the variables significantly associated to an increased liklihood of mortality were Eastern Cooperative Oncology Group performance status(PS),presence of ascites,low level of albumin,elevated level of bilirubin,international normalized ratio(INR) and Log-[(α fetoprotein(AFP)].At multivariate analysis,mortality was independently predicted by bad PS(P < 0.0001),high INR values(P = 0.0001) and elevated Log-(AFP) levels(P = 0.009).CONCLUSION:This study confirms the heterogeneous behavior of untreated HCC.BCLC staging remains an important prognostic guide and may be important in decision-making for palliative treatment. | Giuseppe Cabibbo Marcello Maida Chiara Genco Pietro Parisi Marco Peralta Michela Antonucci Giuseppe Brancatelli Calogero Cammà Antonio Craxì Vito Di Marco | 2012 | World Journal of Hepatology2012，4，9： | 11 |
| 4 | Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure显示文摘Hepatocellular carcinoma(HCC) is the main cause of death in patients with cirrhosis, with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Over time several randomized phase Ⅲ trials have been performed testing sunitinib, brivanib, linifanib and other molecules in head-tohead comparison with Sorafenib as first-line treatment for advanced-stage HCC, but none of these has so far been registered in this setting. Moreover, another feared vacuum arises from the absence of molecules registered as second-line therapy for patients who have failed Sorafenib, representing an urgent unmet medical need. To date all molecules tested as second-line therapies for advanced hepatocellular carcinoma, failed to demonstrate an increased survival compared to placebo. What are the possible reasons for the failure? What we should expect in the near future? | Marcello Maida Massimo Iavarone Maurizio Raineri Calogero Cammà Giuseppe Cabibbo | 2015 | World Journal of Hepatology2015，7，17： | 7 |
| 5 | Hyperferritinemia is a risk factor for steatosis in chronic liver disease显示文摘AIM: To investigate the relationship between ferritin and steatosis in patients with chronically abnormal liver function tests (LFTs) and high ferritin level. METHODS: One hundred and twenty-four consecutive patients with hyperferritinemia (male > 300 ng/mL, female > 200 ng/mL) were evaluated; clinical, biochemical and serological data, iron status parameters, HFE gene mutations and homeostasis model assessment score were obtained. Steatosis was graded by ultrasound as absent or present. Histology was available in 53 patients only. RESULTS: Mean level of ferritin was 881 ± 77 ng/mL in men and 549 ± 82 ng/mL in women. The diagnosis was chronic hepatitis C in 53 (42.7%), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in 57 (45.9%), and cryptogenic liver damage in 14 (11.3%). None was diagnosed as hereditary hemochromatosis (HH). Hepatic siderosis on liver biopsy was present in 17 of 54 (32%) patients; grade 1 in eight and grade 2 in nine. Overall, 92 patients (74.2%) had steatosis. By logistic regression, ferritin and γ-glutamyltransferase were independent predictors of steatosis. Ferritin levels were signifi cantly related to low platelet count, steatosis and hepatitis C virus infection. CONCLUSION: In a non-obese cohort of non-alcoholic patients with chronically abnormal LFTs without HH, high serum ferritin level is a risk factor for steatosis. | Anna Licata Maria Elena Nebbia Giuseppe Cabibbo Giovanna Lo Iacono Francesco Barbaria Virna Brucato Nicola Alessi Salvatore Porrovecchio Vito Di Marco Antonio Craxì Calogero Cammà | 2009 | World Journal of Gastroenterology2009，15，17： | 6 |
| 6 | Magnetic resonance imaging of the cirrhotic liver in the eraof gadoxetic acid显示文摘Gadoxetic acid improves detection and characterization of focal liver lesions in cirrhotic patients and can estimate liver function in patients undergoing liver resection.The purpose of this article is to describe the optimal gadoxetic acid study protocol for the liver,the unique characteristics of gadoxetic acid,the differences between gadoxetic acid and extra-cellular gadolium chelates,and the differences in phases of enhancement between cirrhotic and normal liver using gadoxetic acid.We also discuss how to obtain and recognize an adequate hepatobiliary phase. | Francesco Agnello Marco Dioguardi Burgio Dario Picone Federica Vernuccio Giuseppe Cabibbo Lydia Giannitrapani Adele Taibbi Antonino Agrusa Tommaso Vincenzo Bartolotta Massimo Galia Roberto Lagalla Massimo Midiri Giuseppe Brancatelli | 2016 | World Journal of Gastroenterology2016，22，1： | 4 |
| 7 | Microstructure strengthening mechanisms in different equal channel angular pressed aluminum alloys显示文摘 | Marcello Cabibbo | 2013 | Materials Science & Engineering A2013，，： | 4 |
| 8 | Imaging appearance of treated hepatocellular carcinoma显示文摘Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma(HCC).Although the primary end point of treatment of HCC is survival,radiological response could be a surrogate end point of survival,and has a key role in HCC decision-making process.However,radiological assessment of HCC treatment efficacy is often controversial.There are few doubts on the evaluation of surgical resection;in fact,all known tumor sites should be removed.However,an unenhancing partial linear peripheral halo,in most cases,surrounding a fluid collection reducing in size during follow-up is demonstrated in successfully resected tumor with bipolar radiofrequency electrosurgical device.Efficacy assessment of locoregional therapies is more controversial and differs between percutaneous ablation(e.g.,radiofrequency ablation and percutaneous ethanol injection)and transarterial treatments(e.g.,conventional transarterial chemoembolization,transarterial chemoembolization with drug eluting beads and radioembolization).Finally,a different approach should be used for new systemic agent that,though not reducing tumor mass,could have a benefit on survival by delaying tumor progression and death.The purpose of this brief article is to review HCC imaging appearance after treatment. | Francesco Agnello Giuseppe Salvaggio Giuseppe Cabibbo Marcello Maida Roberto Lagalla Massimo Midiri Giuseppe Brancatelli | 2013 | World Journal of Hepatology2013，5，8： | 3 |
| 9 | Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy显示文摘 | Massimo Iavarone Giuseppe Cabibbo Fabio Piscaglia Claudio Zavaglia Antonio Grieco Erica Villa Calogero Cammà Massimo Colombo | 2011 | Hepatology2011，，6： | 2 |
| 10 | Microstructure and mechanical property studies of AA 6056 friction stir welded plate 显示文摘 | Cabibbo M Mcqueen H J Evangelista E et ol | 2007 | Materials Science and Engineering A2007，46，： | 1 |
| 11 | Creep behavior of INCOLOY alloy 617显示文摘 | Marcello Cabibbo Elisabetta Gariboldi Stefano Spigarelli Dario Ripamonti | 2008 | Journal of Materials Science2008，，8： | 1 |
| 12 | Analysis of the creep strength of a low-carbon AISI 304 steel with low-Σ grain boundaries 显示文摘 | Spigarelli S Cabibbo M Evangelista E Palumbo G | 2003 | Materials Science and Engineering A2003，352，： | 1 |
| 13 | Microstructureand mechanical property studies of AA 6056 friction stir weldedplate显示文摘 | Cabibbo M Mcqueen H J Evangelista E | 2007 | Materials Science and Engineering A2007，，460461： | 1 |
| 14 | Epidemiology, risk factors and surveillance of bepatocellular carcinoma显示文摘 | Cabibbo G Craxi A | 2010 | Eur Rev Med Pharmacol Sci2010，14，4： | 1 |
| 15 | Unitary Symmetry and Leptonic Decays 显示文摘 | Cabibbo N | 1963 | Physical Review Letters1963，10，： | 1 |
| 16 | Exponential hadronic spectrum and quark liberation显示文摘 | Cabibbo N Parisi G | 1975 | Phys Lett1975，59，： | 1 |
| 17 | Creep behavior of INCOLOY alloy 617显示文摘 | Cabibbo M Gariboldi E Spigarelli S | 2008 | Journal of Materials Science2008，43，8： | 1 |
| 18 | Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results显示文摘 | Giuseppe Salvaggio Alessandro Furlan Francesco Agnello Giuseppe Cabibbo Daniele Marin Lydia Giannitrapani Chiara Genco Massimo Midiri Roberto Lagalla Giuseppe Brancatelli | 2014 | La radiologia medica2014，，4： | 1 |
| 19 | Analysis of high-temperature deformation and microstructure of an AZ31 magnesium alloy 显示文摘 | SPIGARELLI S MEHTEDI M E CABIBBO M EVANGELISTA E KANEKO J JAGER A GARTNEROVA V | 2007 | Materials Science and Engineering A2007，462，： | 1 |
| 20 | Investigation on precipitation phenomena of Ni-22Cr- 12Co-9Mo alloy aged and crept at high temperature显示文摘 | Gariboldi E Cabibbo M Spigarelli S | 2008 | International Journal of Pressure Vessels and Piping2008，85，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员